Status:

COMPLETED

Biomarkers in Autosomal Dominant Cerebellar Ataxia

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

Spinocerebellar Ataxia Type 1

Spinocerebellar Ataxia Type 2

Eligibility:

All Genders

18+ years

Brief Summary

Autosomal dominant cerebellar ataxias (ADCA) are a group of neurodegenerative disorders that are clinically and genetically various. BIOSCA study aims to identify markers of the metabolism (energy pro...

Detailed Description

Rational. Autosomal dominant cerebellar ataxias (ADCA) are a clinically heterogeneous group of neurodegenerative disorders caused by unstable CAG repeat expansions encoding polyglutamine tracts. ADCA ...

Eligibility Criteria

Inclusion

  • Inclusion criteria :
  • More than 18 years of age
  • Ability to tolerate MRI
  • Positive genetic test to SCA1, 2, 3 or 7
  • Coverage by social insurance
  • Written informed consent must be obtained from the subject
  • Exclusion criteria :
  • Less than 18 years of age
  • Concomitant significant neurological disorder
  • Unsuitability for MRI, e.g. claustrophobia, metal implants
  • History of significant head injury
  • Unability to receive an informed explanation about the protocol
  • Unability to complete the protocol
  • Non coverage by social insurance
  • No written informed consent obtained

Exclusion

    Key Trial Info

    Start Date :

    November 1 2011

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2015

    Estimated Enrollment :

    102 Patients enrolled

    Trial Details

    Trial ID

    NCT01470729

    Start Date

    November 1 2011

    End Date

    December 1 2015

    Last Update

    September 6 2019

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Groupe Hospitalier Pitié Salpêtrière

    Paris, France, 75013